×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PTN – palatin technologies, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PTN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/10
04:35 pm
ptn
NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN) [Yahoo! Finance]
High
Report
NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN) [Yahoo! Finance]
4/10
04:23 pm
ptn
Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal [Yahoo! Finance]
High
Report
Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal [Yahoo! Finance]
4/10
04:01 pm
ptn
Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal
High
Report
Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal
4/10
07:45 am
ptn
Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting [Yahoo! Finance]
High
Report
Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting [Yahoo! Finance]
4/10
07:30 am
ptn
Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting
Medium
Report
Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting
3/31
07:44 am
ptn
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study [Yahoo! Finance]
Medium
Report
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study [Yahoo! Finance]
3/31
07:30 am
ptn
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
High
Report
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
3/28
07:30 am
ptn
Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177
High
Report
Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177
Date
Time
Symbol
Company Name
Action
%Chg
2/13/2025
07:30 am
PTN
palatin technologies, inc.
BEAT
Report
7.1%
palatin technologies, inc.
2/13/2025
07:30 am
PTN
palatin technologies, inc.
BEAT
Report
7.1%
palatin technologies, inc.
2/13/2025
07:30 am
PTN
palatin technologies, inc.
BEAT
Report
1.0%
palatin technologies, inc.
2/13/2025
07:30 am
PTN
palatin technologies, inc.
BEAT
Report
5.0%
palatin technologies, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/10
05:05 pm
ptn
Form 8-K PALATIN TECHNOLOGIES For: Apr 10
High
Report
Form 8-K PALATIN TECHNOLOGIES For: Apr 10
3/31
08:01 am
ptn
Form 8-K PALATIN TECHNOLOGIES For: Mar 28
High
Report
Form 8-K PALATIN TECHNOLOGIES For: Mar 28
2/14
04:50 pm
ptn
Form SCHEDULE 13G PALATIN TECHNOLOGIES Filed by: ARMISTICE CAPITAL, LLC
Medium
Report
Form SCHEDULE 13G PALATIN TECHNOLOGIES Filed by: ARMISTICE CAPITAL, LLC
2/13
09:15 am
ptn
Form 10-Q PALATIN TECHNOLOGIES For: Dec 31
Low
Report
Form 10-Q PALATIN TECHNOLOGIES For: Dec 31
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
8/6
Palatin Technologies To Present At Canaccord Genuity's 39th Annual Growth Conference
19.5%
6/26 Form 4 PALATIN TECHNOLOGIES For: Jun 24 Filed by: Rossetti Angela 11.0%
9/12 Form 10-K PALATIN TECHNOLOGIES For: Jun 30 6.0%
5/9 Form 10-Q PALATIN TECHNOLOGIES For: Mar 31 5.3%
5/9 Palatin Technologies' (PTN) CEO Carl Spana on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.2%
6/20 Form 8-K PALATIN TECHNOLOGIES For: Jun 20 3.9%
2/5 Form SC 13G/A PALATIN TECHNOLOGIES Filed by: BlackRock Inc. 2.6%
5/11 Palatin Technologies, Inc. (NASDAQ: PTN) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. 2.1%
11/7 Palatin Technologies, Inc. to Report First Quarter Fiscal Year 2020 Results; Teleconference and Webcast to be held on November 13, 2019 2.0%
8/7 Form 4 PALATIN TECHNOLOGIES For: Aug 05 Filed by: Hull Joseph Stanley 1.8%
6/26 Form 4 PALATIN TECHNOLOGIES For: Jun 24 Filed by: Rossetti Angela 11.0%
9/12 Form 10-K PALATIN TECHNOLOGIES For: Jun 30 6.0%
5/9 Form 10-Q PALATIN TECHNOLOGIES For: Mar 31 5.3%
5/9 Palatin Technologies' (PTN) CEO Carl Spana on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.2%
6/20 Form 8-K PALATIN TECHNOLOGIES For: Jun 20 3.9%
2/5 Form SC 13G/A PALATIN TECHNOLOGIES Filed by: BlackRock Inc. 2.6%
5/11 Palatin Technologies, Inc. (NASDAQ: PTN) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. 2.1%
11/7 Palatin Technologies, Inc. to Report First Quarter Fiscal Year 2020 Results; Teleconference and Webcast to be held on November 13, 2019 2.0%
8/7 Form 4 PALATIN TECHNOLOGIES For: Aug 05 Filed by: Hull Joseph Stanley 1.8%
TOP News Decliners
6/21
FDA approves drug for loss of sexual desire in women [Reuters (UK)]
-39.2%
2/10 Q2/2020 12/31/2019 EPS -0.020 ZacksConsensus 0.000 ActVsEst (0.020) - Miss -15.7%
4/30 Form PRE 14A PALATIN TECHNOLOGIES For: Jun 25 -9.8%
6/6 Palatin Technologies Granted FDA Orphan Drug Designation -- PL-8177 for the Treatment of Non-Infectious Uveitis -9.3%
7/1 Palatin Technologies Provides Mid-Calendar Year Corporate Update -8.4%
4/30 Palatin Technologies Provides Assessment of Impact of COVID-19 Pandemic on Business Operations -7.7%
9/12 Palatin Tech up 7% premarket on FY 2019 results [Seeking Alpha] -4.8%
2/6 Palatin Technologies, Inc. to Report Second Quarter Fiscal Year 2020 Results; Teleconference and Webcast to be held on February 11, 2020 -3.4%
11/1 Does Palatin Technologies (NYSEMKT:PTN) Deserve A Spot On Your Watchlist? [Yahoo! Finance News] -3.3%
9/11 Palatin Technologies, Inc. to Report Fourth Quarter & Fiscal Year End 2019 Results; Teleconference and Webcast to be held on September 12, 2019 -3.1%
2/10 Q2/2020 12/31/2019 EPS -0.020 ZacksConsensus 0.000 ActVsEst (0.020) - Miss -15.7%
4/30 Form PRE 14A PALATIN TECHNOLOGIES For: Jun 25 -9.8%
6/6 Palatin Technologies Granted FDA Orphan Drug Designation -- PL-8177 for the Treatment of Non-Infectious Uveitis -9.3%
7/1 Palatin Technologies Provides Mid-Calendar Year Corporate Update -8.4%
4/30 Palatin Technologies Provides Assessment of Impact of COVID-19 Pandemic on Business Operations -7.7%
9/12 Palatin Tech up 7% premarket on FY 2019 results [Seeking Alpha] -4.8%
2/6 Palatin Technologies, Inc. to Report Second Quarter Fiscal Year 2020 Results; Teleconference and Webcast to be held on February 11, 2020 -3.4%
11/1 Does Palatin Technologies (NYSEMKT:PTN) Deserve A Spot On Your Watchlist? [Yahoo! Finance News] -3.3%
9/11 Palatin Technologies, Inc. to Report Fourth Quarter & Fiscal Year End 2019 Results; Teleconference and Webcast to be held on September 12, 2019 -3.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: